To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
Five steps to approving advanced therapy Parkinson’s drugs
Ever wondered how new Parkinson’s medicines make it to market?
7 days ago
Could virtual studies support Parkinson’s disease research?
Parkinson’s research is “hampered by inefficient recruitment and burdensome in-person assessments”, according to researchers in the US and Canada. But could virtual research have the potential to help solve some of these problems? Recruiting 203 participants from Fox Insight – an online clinical study sponsored by The Michael J Fox Foundation – the team assessed the validity of the participants’ self-reported Parkinson’s health information, and their willingness to take part in video-based research. Participants completed online questionnaires and attended two virtual visits, with a movement disorder specialist determining the likely diagnosis compared to the self-reported diagnosis. The study revealed that the participants’ self-reported diagnosis of Parkinson’s was accurate – and that 98.5% of participants would consider participating in a future study with virtual visits. The researchers concluded: “Our study demonstrates the promise of a much-needed novel model for conducting Parkinson’s research and highlights the potential of such a model for ……
2 weeks ago
Gait and tremor may be the best early predictors of Parkinson’s disease
Gait and tremor may be the most identifiable early signs of Parkinson’s disease, according to researchers from the US, France and Germany. The researchers analysed data from two large health-record databases, including an insurance company’s de-identified administrative claims. Selecting 8,382 participants with Parkinson’s disease, the scientists evaluated individual occurrences of reported symptoms over time – and how these corresponded to their Parkinson’s diagnosis. The analysis revealed a “pre-diagnostic window” in which symptoms were reported but no diagnosis of Parkinson’s disease was made. The most dominant symptoms in this pre-diagnostic window were abnormal gait and tremor, highlighting “the existence of a population of [Parkinson’s] patients whose diagnoses can be accelerated”. The researchers concluded: “Accurate, prospective identification of high-risk individuals would allow for earlier diagnosis, intervention and more effective large-scale evaluation of potential therapeutics.”
3 weeks ago
Air pollution may be linked to greater risk of Parkinson’s disease
A study from researchers in South Korea suggests that exposure to nitrogen dioxide (NO2), a gas associated with car and power plant emissions, could increase the risk of Parkinson’s disease. Using Korean National Health Insurance Service data, the researchers identified 78,830 participants above age 40 who had lived in Seoul during a certain time frame – and had not been diagnosed with Parkinson’s disease before 2006. During the study period of January 2007 to December 2015, 338 of the participants were diagnosed with the condition. The team then used participant addresses to determine the degree of air pollution exposure. The analysis revealed that those with the highest NO2 exposure had a “statistically significant” greater risk of being diagnosed with Parkinson’s disease. “These findings suggest that regulation of air pollutants might reduce the incidence of Parkinson’s disease,” wrote the researchers, “advocating for the need to implement a targeted public health policy.”